Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PU-AD in Mild Alzheimer's Disease
NCT04311515Phase 2Terminated
- Sponsor
- Samus Therapeutics
- Start
- Jun 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Icapamespib in Alzheimer's disease (AD), sponsored by Samus Therapeutics. Started Jun 2020; status: terminated.
02
Drugs
Icapamespib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04311515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04311515.